Temodar and Sutent as Therapy for Melanoma
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
|3||Active, not recruiting||
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
† Study has passed its completion date and status has not been verified in more than two years.